, Singapore

Biomedical sciences sector gets S$790M funding boost

S$200 million was also alloted for A*STAR’s Biomedical Research Council.

The Biomedical Sciences Executive Committee has announced new funds to strengthen public-private partnerships.

One was a S$200 million Strategic Positioning Fund for A*STAR’s Biomedical Research Council to support new research areas.

Meanwhile, the basic science and clinical research community can tap on a S$590 million Open Collaborative Fund that is aimed at promoting partnerships between the two. This fund will go towards a range of grants, including:

- S$175 million in grants under the Translational and Clinical Research Flagship Programmes, which is intended for globally competitive research programmes that focus on specific diseases or clinical needs
- S$100 million BMRC-OCF Joint Bench-to-Bedside Fund for small-scale grants towards one-on-one collaborations between basic scientists and clinical investigators
- S$175 million Individual Research Grants for clinician scientists
- S$150 million Cooperative Basic Research Grants for non-clinician scientists

As part of the Research, Innovation and Enterprise 2015 plan, the aim is to foster more partnerships and boost multidisciplinary integration to catalyse clinical solutions.


 

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.